Neoadjuvant anti-programmed death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial
Immunotherapies targeting the PD1/PD-L1 pathway have had a large impact on the treatment of advanced NSCLC. Concerning multimodality tumor therapy, only few trials until today have been performed investigating neoadjuvant treatment with anti PD-1 immunotherapy prior to curative intent surgery. Aim o...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
02 May 2019
|
| In: |
BMC cancer
Year: 2019, Volume: 19 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-019-5624-2 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1186/s12885-019-5624-2 |
| Author Notes: | Florian Eichhorn, Laura V. Klotz, Helge Bischoff, Michael Thomas, Felix Lasitschka, Hauke Winter, Hans Hoffmann and Martin E. Eichhorn |
Search Result 1
Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial
BioMed Central 2019 Universitätsbibliothek Heidelberg 2019
Article (Journal)
Book/Monograph
Online Resource